Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 20/20 | 0.51 |
| ▸ | STAT3 | P40763 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23327181 | 0.94 | TYK2 (0.57) | TYK2STAT3 | |
| Cenacitinib SCHEMBL23327207 | 0.90 | TYK2 (0.49) | TYK2 | |
| Cenacitinib SCHEMBL30548450 | 0.90 | TYK2 (0.49) | TYK2 | |
| SCHEMBL23327200 | 0.88 | TYK2 (0.47) | TYK2STAT3 | |
| SCHEMBL23327725 | 0.87 | TYK2 (0.51) | TYK2STAT3 | |
| SCHEMBL23327765 | 0.86 | TYK2 (0.49) | TYK2STAT3 | |
| SCHEMBL23327763 | 0.85 | TYK2 (0.48) | TYK2STAT3 | |
| SCHEMBL23327497 | 0.85 | TYK2 (0.48) | TYK2STAT3 | |
| Cenacitinib SCHEMBL23327489 | 0.84 | TYK2 (0.54) | TYK2 | |
| Cenacitinib SCHEMBL23327769 | 0.84 | TYK2 (0.54) | TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348478-A1 | TYK2 PSEUDOKINASE LIGANDS | VENTYX BIOSCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11753411-B2 | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 pseudokinase ligands | VENTYX BIOSCIENCES, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20210139486-A1 | TYK2 PSEUDOKINASE LIGANDS | VENTYX BIOSCIENCES, INC. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753411-B2 | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 pseudokinase ligands | TYK2, JAK1, JAK2 | TYK2 1/4885STAT3 376/4885 |
| US-20230348478-A1 | TYK2 PSEUDOKINASE LIGANDS | TYK2, JAK2, PTK2B | TYK2 1/4885STAT3 76/4885 |
| US-20210139486-A1 | TYK2 PSEUDOKINASE LIGANDS | TYK2, JAK2, PTK2B | TYK2 1/4885STAT3 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.